MST5 Antibody

What is Microscale Thermophoresis (MST) and how does it enhance antibody research?

Microscale Thermophoresis (MST) is a biophysical technique that measures the directed movement of molecules along microscopic temperature gradients, which can be used to analyze binding interactions between antibodies and their targets.

MST technology allows researchers to:

• Determine binding affinities of antibodies with nanomolar accuracy

• Study interactions in solution without immobilization requirements

• Measure antibody-antigen interactions using very small sample volumes

• Analyze interactions across a wide range of concentrations

Unlike traditional methods like ELISA or surface plasmon resonance (SPR), MST detects changes in thermophoretic behavior that occur when molecules bind, which depends on size, charge, and hydration shell alterations. This approach provides several advantages for antibody research, including the ability to work with crude samples and measure interactions in near-native conditions .

How does conventional MST differ from heterologous MST for antibody affinity measurements?

MST measurements for antibody affinity determination fall into three main categories:

Heterologous MST represents a significant advancement for determining polyclonal antibody affinities to small molecules that was previously impossible with existing methods. This approach allows for accurate measurement of solution-based binding affinities, even for unstable molecules like heroin, and can be executed in less than an hour compared to much slower equilibrium dialysis methods .

What is the functional difference between MST/MPST antibodies and other protein-specific antibodies?

MPST (3-mercaptopyruvate sulfurtransferase, sometimes abbreviated as MST) antibodies target a specific enzyme that catalyzes the transfer of sulfur from 3-mercaptopyruvate to cyanide or other thiol compounds. These antibodies are distinct from antibodies targeting other proteins in several important ways:

• Target activity: MPST antibodies recognize a protein involved in cyanide detoxification and thiosulfate biosynthesis with weak rhodanese activity

• Cellular localization: Unlike rhodanese (TST), which is mitochondrial, MPST is primarily cytoplasmic, requiring different sample preparation techniques when using these antibodies

• Research applications: MPST antibodies are valuable for studying:

  • Hydrogen sulfide (H₂S) production pathways in the brain, retina, and vascular endothelium

  • Antioxidant mechanisms

  • Synaptic modulation and neuroprotection

  • Cysteine catabolism pathways

When selecting an MPST antibody, researchers should consider the specific isoform they wish to detect and whether their experimental conditions might detect cross-reactivity with the related TST protein.

How should researchers optimize sample preparation for MST antibody-binding experiments?

Optimal sample preparation is critical for accurate MST measurements of antibody interactions:

• Buffer optimization:

  • Use MST-optimized buffers containing 0.05% Tween-20 to prevent adhesion to capillaries

  • Maintain consistent buffer composition between samples and reference measurements

  • Consider ionic strength carefully as it affects thermophoretic behavior

• Fluorescent labeling considerations:

  • For conventional MST, label antibodies using amine-reactive dyes targeting lysine residues (avoid labeling binding sites)

  • For heterologous MST, use hapten-fluorophore conjugates (like MorHap-Cy5 as demonstrated for heroin antibody studies)

  • Optimize dye-to-protein ratio (typically 0.5-1.0) to prevent overmodification

• Concentration parameters:

  • Keep labeled molecule at a constant concentration below the expected Kd (typically 1-10 nM)

  • Titrate binding partner from approximately 0.1× to 10× the expected Kd

  • For polyclonal antibodies, determine total binding site concentration first using equilibrium dialysis with fluorimetry

• Specialized considerations:

  • For unstable ligands (like heroin), prepare fresh immediately before analysis

  • For high background samples (like serum), consider using RED instrument settings with higher IR-laser power (80%) as demonstrated in studies comparing Nanobody and Nanobody-Fc fusion binding to CD38

Careful sample preparation significantly improves the signal-to-noise ratio and reproducibility of MST measurements, particularly when working with complex biological samples.

What controls should be included when validating the specificity of an MST/MPST antibody?

A comprehensive validation strategy for MST/MPST antibodies should include these essential controls:

• Primary specificity controls:

  • Positive control tissues/cells with confirmed MPST expression (e.g., HepG2 cells, liver lysates)

  • Comparison across multiple species when expecting cross-reactivity (human, mouse, rat liver lysates show different banding patterns)

  • Preabsorption controls using immunizing peptide to block antibody binding

• Cross-reactivity assessment:

  • Testing against related enzymes, particularly thiosulfate sulfurtransferase (TST/rhodanese) to confirm specificity

  • Profiling against tissue panels with varying MPST expression levels

  • Assessment in MPST-knockout or knockdown models when available

• Application-specific controls:

  • For Western blotting: Molecular weight verification (~33kDa for human MPST) and recombinant MPST standard

  • For immunohistochemistry: Comparison with mRNA expression data

  • For fluorescence microscopy: Co-localization with cytoplasmic markers (MPST) versus mitochondrial markers (TST)

• Technical controls:

  • Secondary antibody-only controls to assess background

  • Isotype-matched irrelevant antibodies (e.g., anti-GFP mAb) as used in the CD38 binding studies

  • Gradient of antibody concentrations to establish optimal working dilution (typically 0.2-1μg/ml for Western blot)

Proper validation should confirm both analytical specificity (recognition of the intended target) and diagnostic specificity (absence of false positives) across intended applications.

What are the optimal conditions for measuring binding kinetics of bispecific antibodies using MST?

Bispecific antibodies present unique challenges for binding analysis due to their dual targeting capabilities. When using MST to characterize these molecules:

• Experimental design considerations:

  • For BCMA-targeting bispecifics (like teclistamab and elranatamab), analyze binding to BCMA and CD3 separately

  • For GPRC5D-targeting bispecifics (like talquetamab), consider altered binding properties compared to monospecific antibodies

  • Design experiments to assess potential avidity effects when both arms can engage simultaneously

• Technical parameters:

  • Temperature: Standard 25°C for most applications, but consider physiological 37°C for therapeutic antibodies

  • MST power: 80% power typically provides optimal signal-to-noise ratio

  • Capillary selection: Premium coated capillaries recommended for bispecific antibodies to minimize adhesion effects

  • Incubation time: Allow 10-15 minutes for binding equilibration before measurement

• Data analysis approach:

  • Fit binding curves using specialized models that account for potential bivalent binding

  • Compare apparent Kd values across different target proteins to understand target preference

  • Correlate binding kinetics with functional data (e.g., T cell activation, cytotoxicity)

• Control measurements:

  • Include parent antibodies when available

  • Test binding to individual antigenic domains

  • Verify structural integrity using orthogonal methods (SEC, DLS)

Properly designed MST experiments can provide valuable insights into how bispecific antibodies like teclistamab (BCMA×CD3) engage their targets and predict their clinical efficacy, as demonstrated by the correlation between strong binding affinity and the two-year median duration of response observed in clinical trials .

How can fragment-based computational design improve targeted antibody development?

Fragment-based computational design represents a cutting-edge approach to developing antibodies against predetermined epitopes. This method offers several advantages over traditional antibody discovery:

• Design principles:

  • Combinatorial design of antibody Complementarity Determining Region (CDR) loops

  • Grafting of designed motifs onto stable antibody scaffolds

  • Optimization for solubility and conformational stability

• Methodology overview:

  • Identification of protein fragments that interact with target epitopes

  • Assembly of these fragments into potential CDR loops

  • Structural matching to compatible antibody scaffolds

  • Computational refinement of stability and binding

• Experimental validation:

  • Studies have generated single-domain antibodies targeting various antigens including:

    • SARS-CoV-2 spike protein receptor-binding domain

    • Human serum albumin (HSA)

    • Pancreatic bovine trypsin

  • These computationally designed antibodies demonstrated:

    • Stable folding properties

    • Nanomolar binding affinities without in vitro affinity maturation

    • Correct targeting of predetermined epitopes

• Critical advantages:

  • Rapid generation of lead antibodies (process can run on a standard laptop)

  • Precise epitope targeting, including challenging concave epitopes

  • Reduced dependency on high-resolution structural data

    • Similar predictions obtained when using crystal structures or computational models

This approach has tremendous potential for therapeutic antibody development, particularly in rapid response scenarios like emerging infectious diseases, where structural prediction can substitute for experimentally determined structures.

What are the limitations of using murine models for evaluating engineered therapeutic antibodies?

Researchers should be aware of significant species-specific differences when evaluating engineered antibodies in mice:

• FcRn binding disparities:

  • Human and mouse FcRn (neonatal Fc receptor) have substantial differences in binding specificity

  • Engineered human IgG1 antibodies can show contradictory properties between murine and human systems

  • A human IgG1 mutant (HN mutant) with enhanced transport in human FcRn assays showed unexpectedly short in vivo persistence in mice

• Experimental evidence of species limitations:

  • The HN-mutated human IgG1 demonstrated:

    • Improved transport in human FcRn functional assays

    • Paradoxically short in vivo persistence in mice (62.8 ± 2.7h vs. 250.6 ± 15.3h for wild-type)

    • Competitive inhibition of FcRn activity in mice (acting as an "Abdeg" - antibody that enhances IgG degradation)

• Pharmacokinetic considerations:

  • Reduced pH dependence of engineered antibodies can create opposite effects across species

  • High-affinity binding to murine FcRn may result in poor recycling rather than extended half-life

  • Rapid clearance in mice might incorrectly suggest poor therapeutic efficacy

• Alternative evaluation approaches:

  • In vitro assays with human FcRn-transfected cell lines

  • Humanized FcRn mouse models

  • Ex vivo human tissue analyses

  • Careful correlation of binding kinetics to functional outcomes

These findings highlight the need for cautious interpretation of murine preclinical data, especially for engineered antibodies where relatively small differences in receptor interactions can dramatically impact pharmacokinetics and efficacy.

How can high-throughput interaction analysis systems optimize antibody library screening?

Modern antibody development benefits greatly from high-throughput screening systems that integrate sequence analysis with functional characterization:

• Integrated workflow components:

  • Transformation with plasmid libraries containing various antibody sequences

  • Culture of single colonies in 96-well plates

  • Sequence analysis using bacterial cells

  • Recombinant antibody secretion into supernatant

  • Immobilization on sensor chips

  • High-throughput Surface Plasmon Resonance (SPR) analysis

• Performance capabilities:

  • Complete process from transformation to 384 interaction analyses within one week

  • Parallel evaluation of mutations across all CDR residues

  • Simultaneous testing against multiple antigens (e.g., human and mouse PD-1)

• Application to interspecies specificity design:

  • BreviA system was used to analyze an anti-human PD-1 antibody (toripalimab)

  • Alanine and tyrosine scanning of all CDR residues revealed mutations that enhanced cross-reactivity with mouse PD-1

  • Deep mutational scanning identified specific mutants with >100-fold increased affinity for mouse PD-1

• Methodological advantages:

  • Eliminates bottlenecks in traditional antibody screening

  • Provides quantitative binding data rather than simple yes/no binding results

  • Enables data-driven design through systematic analysis of structure-function relationships

  • Allows specific targeting of binding properties (e.g., cross-reactivity, specificity, affinity)

This approach represents a significant advancement over traditional screening methods by providing comprehensive kinetic data for hundreds of antibody variants, facilitating rational antibody engineering.

How do bispecific antibodies differ in their clinical efficacy and management compared to conventional antibody therapies?

Bispecific antibodies represent a significant advancement in immunotherapy with unique clinical considerations:

• Mechanism of action differences:

  • Bispecific antibodies simultaneously target two antigens:

    • One arm targets a tumor antigen (e.g., BCMA or GPRC5D on myeloma cells)

    • Second arm targets CD3 on T cells

  • This dual targeting redirects T cells to tumor cells, inducing cytotoxicity without requiring engineering of the patient's T cells (unlike CAR-T therapy)

• Clinical efficacy parameters:

  • Response rates: Approximately two-thirds of patients respond to bispecific antibodies

  • Time to first response: Typically around one month

  • Time to best response: Approximately three months

  • Median duration of response: At least two years for teclistamab and elranatamab

• Administration considerations:

  • Dosing schedule: Initially weekly treatments for six months, then every two weeks

  • Administration route: Subcutaneous injection versus IV infusion (emerging options)

  • Treatment duration: Currently until disease progression, though fixed-duration protocols are being developed

• Patient selection factors:

  • Reduced efficacy observed in patients with:

    • Poor cytogenetics

    • Extramedullary disease (EMD)

    • High beta-2 microglobulin levels (>5.5 mg/L)

    • Penta-refractory disease (refractory to two IMiDs, two proteasome inhibitors and one CD38 antibody)

• Advantages compared to CAR-T therapy:

  • "Off-the-shelf" availability without manufacturing delays

  • Immediate administration for rapidly progressing disease

  • No requirement for lymphodepletion

  • Potentially more consistent product quality

These clinical insights demonstrate how bispecific antibodies like teclistamab, elranatamab (targeting BCMA), and talquetamab (targeting GPRC5D) are creating new options for treating multiple myeloma patients.

What methodological approaches can best determine antibody responses in infectious disease outbreaks?

Accurate assessment of antibody responses during infectious disease outbreaks requires robust methodological approaches:

• Temporal sampling strategy:

  • Multiple timepoint sampling provides crucial data on antibody kinetics

  • A SARS-CoV-2 outbreak study among Marine recruits demonstrated:

    • 97.3% persistence of RBD IgG antibodies from 6 to 10 weeks post-outbreak

    • Reduction in IgM positivity from 67.3% at 6 weeks to 43.1% at 10 weeks

    • Correlation between PCR-confirmed infection and subsequent antibody development

• Multimodal testing approach:

  • Combining molecular (PCR) and serological testing provides complementary data

  • Targeting multiple antibody isotypes (IgG, IgM, IgA) offers comprehensive immune response profiling

  • Including functional antibody assays (neutralization) alongside binding assays provides clinically relevant information

• Target antigen selection:

  • For SARS-CoV-2, the receptor-binding domain (RBD) of the spike protein has proven highly informative

  • Multiple antibody targets can differentiate between vaccine-induced and infection-induced responses

  • Understanding epitope immunodominance informs both diagnostics and therapeutic antibody development

• Assay considerations:

  • MST can provide quantitative antibody affinity measurement in infection samples

  • Heterologous MST allows assessment of polyclonal responses to variants and escape mutants

  • Coupling serological studies with clinical outcomes data enhances epidemiological understanding

This comprehensive approach to antibody response characterization provides vital information during outbreaks, informing both immediate patient care decisions and longer-term public health strategies.

How can real-world evidence complement clinical trials in evaluating bispecific antibody therapies?

Real-world evidence collection offers valuable insights that complement formal clinical trials for bispecific antibodies:

• Scope of real-world data collection:

  • Patient experience factors: Outpatient versus inpatient administration, caregiver burden

  • Treatment modifications: Frequency of switching to bi-weekly administration, use of monthly dosing

  • Infection management: Real-world infection rates, use of IVIG for infection prevention

  • Treatment discontinuation and retreatment patterns

• Implementation methodology:

  • Patient surveys to capture experience data

  • Electronic health record (EHR) integration to access objective clinical data

  • Anonymized data sharing with research community

  • Cross-institutional collaboration (e.g., partnership between HealthTree and International Myeloma Society)

• Complementary value to clinical trials:

  • Broader patient population not limited by strict inclusion/exclusion criteria

  • Extended follow-up beyond trial duration

  • Detection of rare adverse events

  • Insights into sequencing with other therapies (before/after CAR-T, etc.)

• Impact on clinical practice:

  • Real-world data can identify optimal patient selection criteria

  • Documentation of treatment modifications that improve tolerability

  • Evidence for treatment discontinuation strategies to reduce hospital visits

  • Understanding of global access disparities

This approach enables 100% of patients receiving bispecific antibody therapy to contribute to research, rather than only those eligible for clinical trials, accelerating knowledge accumulation and practice improvement.

How can researchers address the specific toxicity patterns associated with different bispecific antibody targets?

Different bispecific antibody targets exhibit distinct toxicity profiles that require specific management strategies:

• GPRC5D-targeting antibodies (e.g., talquetamab):

  • Mechanism: GPRC5D expression on skin, nails, and tongue epithelium

  • Manifestations:

    • Skin rash

    • Nail toxicity

    • Dysgeusia and oral mucositis

    • Weight loss due to taste alterations

  • Management strategies:

    • Proactive nutritional support

    • Taste-enhancing approaches

    • Dermatological interventions for skin/nail symptoms

• BCMA-targeting antibodies (e.g., teclistamab, elranatamab):

  • Different toxicity profile related to BCMA expression pattern

  • Closer monitoring for cytokine release syndrome (CRS)

  • Implementation of step-up dosing schedules to mitigate initial inflammatory response

• Cytokine release management (applicable to all bispecifics):

  • Premedication protocols

  • Emergency management algorithms

  • Patient education regarding early symptoms

  • Specialized nursing education

• Infection risk mitigation:

  • Prophylactic antibiotics consideration

  • IVIG administration (frequency determined by real-world data)

  • Vaccination timing relative to therapy initiation

  • Regular monitoring of immunoglobulin levels

Understanding these target-specific toxicity profiles enables researchers to develop targeted management strategies and design next-generation bispecifics with improved safety profiles.

What factors influence the stability and degradation protection of antibody-antigen complexes?

Antibody-antigen binding can significantly affect stability and protection from degradation:

• Enzyme degradation protection:

  • Heterologous MST studies revealed that heroin is protected from serum esterase degradation when bound to antibodies

  • This protection occurs in a concentration-dependent manner

  • Similar protection mechanisms may apply to other enzyme-labile compounds when complexed with antibodies

• Structural determinants of binding stability:

  • Analysis of opioid antibody binding revealed specific molecular moieties critical for stable interactions

  • Structural modifications at the tertiary nitrogen and C-14 position of heroin dramatically reduced binding to TT-6-AmHapAbs

  • These insights enable rational design of hapten antigens to elicit antibodies with desired binding properties

• Methodological approaches to stability assessment:

  • Heterologous MST can measure antibody protection effects on unstable ligands

  • Stability can be monitored over time by repeated binding measurements

  • Comparison with equilibrium dialysis combined with ultra-performance liquid chromatography/tandem mass spectrometry (ED-UPLC/MS/MS) provides complementary data

• Applications in therapeutic antibody design:

  • Understanding stabilization mechanisms informs antibody engineering to enhance target protection

  • Protection from enzymatic degradation can improve efficacy of antibody therapies targeting labile compounds

  • These principles apply to development of vaccines against substances of abuse and other small molecule targets

These findings demonstrate how antibodies can function not only as binding agents but also as protective shields against target degradation, with important implications for therapeutic applications.

How does antibody affinity determination differ between monoclonal, polyclonal, and bispecific antibodies?

Different antibody types require specialized approaches for accurate affinity determination:

For polyclonal antibodies specifically:

• Binding site concentration determination is critical and can be achieved through:

  • Linear regression at fractional binding values between 0 and 1

  • Second derivative analysis of 4-parameter logistic model

  • Equilibrium dialysis with fluorescence detection (ED-fluorimetry)

• Affinity range determination requires:

  • Competitive binding analysis

  • Heterologous approach using modest-affinity labeled tracers

  • Careful analysis of binding curves for evidence of multiple affinity populations

These specialized approaches enable accurate characterization of complex antibody preparations, facilitating both research applications and therapeutic development.

How is trispecific antibody development advancing beyond current bispecific technologies?

Trispecific antibodies represent the next frontier in immunotherapy development, building upon the success of bispecific antibodies:

• Design approaches:

  • Single antibodies capable of targeting two different antigens on tumor cells plus CD3 on T cells

  • Examples under development include:

    • GPRC5D + BCMA + CD3 trispecific antibodies

    • BCMA + CD38 + CD3 trispecific antibodies

• Theoretical advantages:

  • Reduced tumor escape through simultaneous targeting of multiple tumor antigens

  • Potential to overcome resistance mechanisms to single-target therapies

  • Enhanced T cell engagement and activation

  • Reduced dosing frequency through improved target binding and retention

• Technical challenges:

  • Increased structural complexity

  • Manufacturing consistency

  • Potential for unintended cross-reactivity

  • Optimization of binding affinities across three distinct targets

• Clinical development considerations:

  • Need for step-up dosing schedules to manage cytokine release

  • Careful epitope selection to avoid interfering with effector cell recruitment

  • Balance between efficacy and off-target toxicity

  • Potential for fixed-duration treatment regimens

These trispecific approaches may provide solutions to resistance mechanisms that emerge with single-target or bispecific therapies, particularly in diseases like multiple myeloma where antigen modulation and loss are recognized escape mechanisms.

What role does high-throughput structural analysis play in modern antibody engineering?

High-throughput structural analysis has become an essential component of modern antibody engineering:

• Integration with computational design:

  • Fragment-based computational design methods leverage structural databases to identify protein fragments that can interact with target epitopes

  • These fragments are assembled into potential CDR loops

  • Structural matching algorithms identify compatible antibody scaffolds for grafting

• Reduced dependency on experimental structures:

  • Recent advances in ab initio structure prediction enable accurate antibody modeling

  • The SARS-CoV-2 antibody design studies demonstrated that computational models yield comparable design results to experimentally determined structures

  • This capability is particularly valuable for emerging disease targets where structural determination may lag

• Epitope accessibility analysis:

  • Computational assessment of epitope accessibility across diverse antigens showed:

    • 81.4% of epitopes can be targeted by the fragment-based design approach

    • Median density of 19 designed CDRs per nm² of antigen surface

    • Identification of structural features making certain epitopes challenging to target

• Structural validation of designs:

  • Biophysical characterization of designed antibodies confirmed:

    • Stable folding into expected structures

    • Specific binding to intended epitopes

    • Nanomolar binding affinities without affinity maturation

This integration of structural analysis with computational design significantly accelerates antibody development and enables precise targeting of predetermined epitopes, reducing the time and cost of therapeutic antibody discovery.

How can nanobody technology complement traditional antibody approaches in research applications?

Nanobodies offer unique advantages that complement traditional antibodies in various research contexts:

• Structural and biophysical advantages:

  • Nanobodies consist of a single variable domain (VHH) derived from camelid heavy-chain antibodies

  • Their small size (~15 kDa) allows access to cryptic epitopes inaccessible to conventional antibodies

  • The extended CDR3 loops can penetrate cavities on antigens

  • Greater stability under harsh conditions compared to conventional antibodies

• Binding kinetics comparison:

  • MST analysis comparing nanobodies and nanobody-Fc fusion proteins to human CD38 revealed:

    • Both formats maintain high binding affinity

    • The fusion with Fc domains can modify binding kinetics

    • MST analysis at 80% laser power provided optimal signal-to-noise ratio for binding analysis

• Experimental applications:

  • Super-resolution microscopy benefits from the small size of nanobodies

  • Intracellular targeting applications (intrabodies)

  • In vivo imaging with rapid tissue penetration and clearance

  • Crystallization chaperones for structural biology

• Engineering flexibility:

  • Straightforward multimerization to create bi- and tri-specific constructs

  • Fusion with various functional domains (Fc, enzymes, fluorophores)

  • Bacterial expression systems enable cost-effective production

  • Enhanced thermal and chemical stability enables diverse applications

These properties make nanobodies valuable complements to conventional antibodies, particularly in applications requiring small size, stability, or access to challenging epitopes.